A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)

Part of paid clinical trials in Doral, Florida.

Sponsor
GlaxoSmithKline
Study ID
NCT07780669
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • GSK5784283 — DRUG
    GSK5784283 will be administered.
  • Placebo — DRUG
    Placebo will be administered.
  • Standard of care — DRUG
    Standard of care will be administered.

Study Details

The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.

Key Dates

First listed
Aug 21, 2026
Start date
Aug 27, 2026
Status verified
Sep 2026
Primary completion
Jul 20, 2029
Completion
Mar 15, 2030

Study Design

Enrollment
624 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Participants receiving GSK5784283 plus standard of care
  • Placebo Comparator: Participants receiving matching placebo plus standard of care

Primary Outcome Measure

Annualized rate of moderate or severe COPD Exacerbations [ Time Frame: Up to Week 78 ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
GSK Investigational SiteDoralFlorida33172
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Alan Kaufman (PRINCIPAL_INVESTIGATOR)
GSK Investigational SiteLake CharlesLouisiana70605
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Jason Langhofer (PRINCIPAL_INVESTIGATOR)

Find similar trials in Doral, FL

Nationwide
COPD trialsPulmonology trialsLung disease trials
By condition
COPD
By specialty
PulmonologyLung disease
By research site
GSK Investigational Site· Doral, FLGSK Investigational Site· Lake Charles, LA

Related Studies